A Single Supratherapeutic Dose of Atogepant Does Not Affect Cardiac Repolarization in Healthy Adults: Results From a Randomized, Single-Dose, Phase 1 Crossover Trial.

R, Boinpally; B, McNamee; L, Yao; M, Butler; D, McGeeney; L, Borbridge; A, Periclou

doi:10.1002/cpdd.940

Public

A Single Supratherapeutic Dose of Atogepant Does Not Affect Cardiac Repolarization in Healthy Adults: Results From a Randomized, Single-Dose, Phase 1 Crossover Trial.

Shared by NobleBlocks on May 4, 2021 • 12:00 AM UTC

Authors:

Boinpally R

McNamee B

Yao L

Abstract

Atogepant is a selective, oral calcitonin gene-related peptide receptor antagonist in development for preventive treatment of migraine. This randomized, double-blind, phase 1 crossover study evaluated the cardiac repolarization effect of a single supratherapeutic (300 mg) atogepant dose vs placebo i...

Subject

Migraine Disorders

Calcitonin gene-related peptide receptor antagonist

Thorough Qt Study

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!